Anzeige
Mehr »
Login
Samstag, 05.10.2024 Börsentäglich über 12.000 News von 690 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DS8K | ISIN: AU0000226177 | Ticker-Symbol:
NASDAQ
04.10.24
21:25 Uhr
1,855 US-Dollar
-0,225
-10,82 %
Branche
Getränke/Tabak
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
INNOVATION BEVERAGE GROUP LIMITED Chart 1 Jahr
5-Tage-Chart
INNOVATION BEVERAGE GROUP LIMITED 5-Tage-Chart
ACCESSWIRE
113 Leser
Artikel bewerten:
(0)

Innovation Beverage Group Limited Announces Pricing of $5.4 Million Initial Public Offering on the Nasdaq Capital Market Under Symbol "IBG"

SYDNEY, AUSTRALIA / ACCESSWIRE / September 26, 2024 / Innovation Beverage Group Limited ("IBG" or the "Company"), a developer, manufacturer, marketer, exporter and retailer of a growing beverage portfolio of 60 formulations across 13 alcoholic and non-alcoholic brands with a focus on premium and super premium brands, today announced the pricing of its initial public offering (the "Offering") of 1,350,000 ordinary shares, at a public offering price of $4.00 per share for total gross proceeds to the Company of $5.4 million, before deducting underwriting discounts and offering expenses. In addition, the Company has granted a 30-day option to the underwriters to purchase up to an additional 202,500 ordinary shares solely to cover over-allotments, if any.

The ordinary shares are expected to begin trading on The Nasdaq Capital Market, under the symbols "IBG", on September 26, 2024. The Offering is expected to close on or about September 27, 2024, subject to satisfaction of customary closing conditions.

The Benchmark Company, LLC is acting as sole book-running manager for the Offering. Sichenzia Ross Ference Carmel LLP is serving as legal counsel to the Company.

A registration statement on Form F-1 (No. 333-266965) relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission (the "SEC") on September 25, 2024. The Offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, on the SEC's website, www.sec.gov, or by contacting The Benchmark Company, LLC, 150 East 58th Street, #17, New York, New York 10155, at (212) 312-6700.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Innovation Beverage Group Limited

Innovation Beverage Group Limited is a developer, manufacturer, marketer, exporter and retailer of a growing beverage portfolio of 60 formulations across 13 alcoholic and non-alcoholic brands with a focus on premium and super premium brands. The Company owns exclusive manufacturing rights in its beverage portfolio. The Company's products are sold in both the United States and Australian markets. To learn more, go to https://www.innovationbev.com/.

Safe Harbor Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "may", "could", "expects", "projects," "intends", "plans", "believes", "predicts", "anticipates", "hopes", "estimates" and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the Company's control. Actual results (including the anticipated benefits of the offering described herein) may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in the Company's filings with the Securities and Exchange Commission. The forward-looking statements are applicable only as of the date on which they are made, and the Company does not assume any obligation to update any forward-looking statements.

Investor Relations Contact:

TraDigital IR
John McNamara
917-658-2602
John@tradigitalir.com

SOURCE: Innovation Beverage Group

© 2024 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.